SymlinPen®
(pramlintide acetate)
pen-injector

FDA Required REMS Safety Information

- Risk of severe hypoglycemia with use of SYMLIN added to mealtime insulin
- Importance of insulin dose reduction
- Proper Patient Selection

Important Safety Update

Dear [Professional Organization],

The FDA has required AstraZeneca to distribute this safety update to your organization as part of their SYMLIN REMS (Risk Evaluation and Mitigation Strategy) program. We request that you inform your members about the following serious risks of SYMLIN (pramlintide acetate):

- Increased risk of severe hypoglycemia, particularly in patients with type 1 diabetes.
- Importance of insulin dose reduction

Counsel and instruct your patients on insulin dose reduction to minimize the risk of hypoglycemia.

- Proper patient selection. SYMLIN is contraindicated in patients with any of the following:
  - Hypoglycemia unawareness
  - Confirmed gastroparesis
  - Serious hypersensitivity to SYMLIN or any of its product components

A non-promotional fact sheet, reviewed by the FDA, with more detailed safety information is available.

This letter does not contain the complete safety profile for SYMLIN. Please visit www.SymlinREMS.com for more information.

INDICATION: SYMLIN is an amylin analog indicated for patients with type 1 or type 2 diabetes who use mealtime insulin and have failed to achieve desired glycemic control despite optimal insulin therapy.

James W. Blasetto MD, MPH
VP US Medical Affairs, Evidence Generation

AstraZeneca

SYMLIN and SymlinPen are registered trademarks of the AstraZeneca group of companies.